Leap Therapeutics reported that while the study showed some activity in biomarker populations, it failed to produce a decisive positive signal. The study's data suggested a high level of ...
Shares of Leap Therapeutics, Inc. nosedived more than 70% to an all-time low on Tuesday, making them the top loser across U.S. exchanges. The sharp drop — Leap’s worst intraday fall ever ...
Leap Therapeutics, Inc.'s DKN-01 showed disappointing results in the DisTinGuish trial for gastric and gastroesophageal junction cancer. The DeFianCe trial in colorectal cancer was closer to ...
H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data updates from two ongoing Phase 2 studies, DeFianCe and ...
Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...
Leap Therapeutics stock opened at $0.52 on Wednesday. Leap Therapeutics has a one year low of $0.51 and a one year high of $4.79. The company has a 50-day simple moving average of $2.78 and a 200 ...
Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Leap Therapeutics (LPTX – Research Report) and Immunovant (IMVT – Research Report). Leap ...
The updated corporate presentation posted on Leap Therapeutics’ website on the same day provided further insight into the potential of sirexatamab (DKN-01) in various cancer treatments ...
Investing.com -- Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its DisTinGuish study of sirexatamab combined with tislelizumab and ...